leisure time -WSS

leisure time

author：focus 2025-09-05 13:44:14 - browse：51212

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Problems with a popular proposal to regulate AI in health care

WSS

Removing probiotics from the NICU could threaten preemies' health

Victims of gun violence feel impacts long after bullet wound

FDA approves potent Eli Lilly obesity drug, Zepbound

Devoted Health’s losses in Medicare Advantage persist

Bernie brings in new pharma CEOs to talk drug prices

Medicare Advantage plans can’t deny care with AI, CMS warns

focus

leisure time

leisure time

Bright Health sells Medicare Advantage business to Molina

Devoted Health’s losses in Medicare Advantage persist

Medical records are filled with copy

Unique patient identifier: Experts argue the benefits, pitfalls

Jerome Adams on the need for new antivirals for Covid

A protest over insulin prices is seen as a fight for life

DIEP, the 'gold standard' of breast reconstruction, is under threat

HPV cancer vaccine study demonstrates efficacy

Guidelines to prevent youth baseball injuries need more muscle

Readout Newsletter: Amgen, Regeneron, BGI Group and more

focus

Excited delirium, Elijah McClain, and emergency physicians

Medicare will require more price transparency from hospitals

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

What’s missing from the debate over nursing home staff minimums

UCSF medical school apologizes for unethical prisoner experiments

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

entertainment

hotspot

hotspot

explore